NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: NanoViricides Coverage Initiation and Antiviral Pipeline
NanoViricides (NYSE American: NNVC) received an 'Outperform' rating and $6 price target from Noble Capital Markets analyst Robert LeBoyer. The company's lead broad-spectrum antiviral candidate NV-387 is advancing toward Phase II trials, targeting multiple viral diseases including RSV, COVID, and MPOX.
Independent analyst Robert LeBoyer of Noble Capital Markets initiated coverage with an 'Outperform' rating and a $6.00 price target.
NV-387 is the lead broad-spectrum antiviral drug candidate, being developed for RSV, COVID, Long COVID, Influenza, MPOX/Smallpox, Measles, and other respiratory viral infections.
The company has received FDA Orphan Drug Designation and filed for Rare Pediatric Disease Designation for measles.
NV-CoV-2 (API NV-387) is a nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir, while NV-CoV-2-R encapsulates remdesivir within its polymeric micelles.
NanoViricides licenses technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
President and Executive Chairman Anil R. Diwan participated in a Fireside Chat published by StockInvestor Daily’s IPO-Edge program.
The company is currently focused on advancing NV-387 into Phase II human clinical trials.
The company is developing drugs against oral and genital Herpes, viral eye diseases (EKC and herpes keratitis), H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.